A scientist leading the development of Oxford University’s coronavirus vaccine says the just-started phase 2/3 trial only has a 50:50 chance of success, because the virus is diminishing so quickly in the UK.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,